Also known as: Barrett's Esophagus (Barrett's Metaplasia)
Barrett's esophagus is a condition where the normal lining of the esophagus is replaced by tissue similar to the intestinal lining, usually as a result of chronic acid reflux. It is considered a precancerous condition requiring regular monitoring.
Barrett's esophagus affects an estimated 1-5% of the general population and is found in approximately 5-15% of patients undergoing endoscopy for GERD symptoms. It represents the replacement of normal squamous epithelium with specialized intestinal metaplasia (columnar epithelium with goblet cells).
The condition develops as a consequence of chronic gastroesophageal reflux, where repeated acid and bile exposure damages the esophageal lining. The body replaces the damaged tissue with a type more resistant to acid, but this metaplastic tissue carries a small but significant risk of progressing to esophageal adenocarcinoma.
The annual risk of progression from Barrett's esophagus to esophageal cancer is approximately 0.5% per year (1 in 200). This risk increases with the presence of dysplasia (precancerous cellular changes). Low-grade dysplasia carries a progression rate of approximately 0.7% per year, while high-grade dysplasia has a progression rate of approximately 7% per year.
Regular endoscopic surveillance with biopsies is recommended to detect dysplasia early, when it can be treated with minimally invasive endoscopic therapies before cancer develops.
People with Barrett's Esophagus often experience the following symptoms.
Most patients experience chronic heartburn, acid regurgitation, and other typical GERD symptoms, though some patients with Barrett's may have reduced acid sensitivity and fewer symptoms despite significant reflux.
Difficulty swallowing may develop from esophageal stricture formation or, concerning, may indicate progression to cancer. Any new dysphagia warrants prompt evaluation.
Non-cardiac chest pain related to esophageal dysmotility or inflammation. This should be distinguished from cardiac causes.
Some patients are diagnosed incidentally during endoscopy for other reasons. The absence of symptoms does not exclude Barrett's esophagus.
Certain factors may increase your likelihood of developing Barrett's Esophagus.
Common approaches to managing barrett's esophagus. Always consult a healthcare provider for personalized treatment.
Long-term PPI therapy to control acid reflux, promote healing, and potentially reduce the risk of dysplasia progression. PPIs are considered the foundation of Barrett's management.
Regular endoscopy with systematic biopsies to monitor for dysplasia. Frequency depends on findings: every 3-5 years for non-dysplastic Barrett's, more frequently with dysplasia.
A catheter-based treatment that uses radiofrequency energy to destroy Barrett's tissue, allowing normal esophageal lining to regrow. The primary endoscopic therapy for dysplastic Barrett's.
Removal of visible nodular or raised areas within Barrett's segments, often combined with ablation. Used for staging and treating early mucosal cancer or high-grade dysplasia.
Upper endoscopy revealing salmon-colored mucosa extending above the gastroesophageal junction, confirmed by biopsy showing specialized intestinal metaplasia with goblet cells. The Seattle protocol (4-quadrant biopsies every 1-2 cm) is standard for surveillance.
See a doctor if you have long-standing heartburn, difficulty swallowing, or unintentional weight loss. Anyone with GERD symptoms for more than 5 years should discuss endoscopic screening with their doctor.
Steps that may help reduce the risk of developing or worsening barrett's esophagus.
Effective long-term GERD treatment and acid suppression
Weight loss for overweight individuals
Avoid smoking (associated with both GERD and cancer progression)
Screening endoscopy for high-risk individuals with chronic GERD
If left untreated or poorly managed, barrett's esophagus may lead to:
No. The vast majority of people with Barrett's esophagus never develop cancer. The annual risk is approximately 0.5%, but regular surveillance allows early detection and treatment of any precancerous changes.
Ablation treatments can successfully eliminate Barrett's tissue in most patients, with normal esophageal lining regrowing. However, continued PPI therapy and surveillance are still recommended as recurrence is possible.
For Barrett's without dysplasia, every 3-5 years. With low-grade dysplasia, every 6-12 months or treatment. High-grade dysplasia typically warrants treatment rather than surveillance alone.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.